Drug search by name

Mycophenolate Suspension and Renal dysfunction

Result of checking the interaction of drug Mycophenolate Suspension and disease Renal dysfunction for safety when used together.

Check result:

Mycophenolate Suspension <> Renal dysfunction

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Mycophenolate undergoes complete presystemic metabolism to its active form, MPA . Less than 1% of MPA is excreted in the urine. In a single-dose study, the area under the curve (AUC) for MPA in patients with severe chronic renal impairment (creatinine clearance <25 mL/min) was approximately 75% greater than those of healthy volunteers (creatinine clearance >80 mL/min). The AUC for the inactive metabolite was 3 to 6 times higher. Multiple dose studies have not been performed. No data are available for cardiac transplant patients with severe renal impairment and when benefit outweighs risk, therapy with mycophenolate should be administered with extreme caution.

References:

Deierhoi MH, Kauffman RS, Hudson SL, Barber WH, Curtis JJ, Julian BA, Gaston RS, Laskow DA, Diethelm AG "Experience with mycophenolate mofetil (RS61443) in renal transplantation at a single center." Ann Surg 217 (1993): 476-82;disc. 482-4
Bullingham R, Monroe S, Nicholls A, Hale M "Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration." J Clin Pharmacol 36 (1996): 315-24
Keown P, Hayry P, Mathew T, Morris P, Stiller C, Barker C, Carr L, Landsberg D, Hardie I, Rigby R, Isoniemi H, Gray D, Belitsk "A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation, by the tricontinental mycophenolate mofetil renal transplantation study group." Transplantation 61 (1996): 1029-37
Sollinger HW, Belzer FO, Deierhoi MH, Diethelm AG, Gonwa TA, Kauffman RS, Klintmalm GB, McDiarmid SV, Roberts J, Rosenthal JT, et al "RS-61443 (mycophenolate mofetil). A multicenter study for refractory kidney transplant rejection." Ann Surg 216 (1992): 513-8;disc. 518-9
"Product Information. CellCept (mycophenolate mofetil)." Roche Laboratories, Nutley, NJ.
Bullingham RES, Nicholls A, Hale M "Pharmacokinetics of mycophenolate mofetil (RS61443): a short review." Transplant Proc 28 (1996): 925-9

Mycophenolate Suspension

Generic Name: mycophenolate mofetil

Brand Name: Cellcept, Myfortic, MMF

Synonyms: Mycophenolate mofetil (oral/injection), Mycophenolate

What is Mycophenolate Suspension?